How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Patient-controlled Analgesic Pump Market
- By Product Type: Intravenous PCA Pumps, Epidural PCA Pumps, Subcutaneous PCA Pumps, Transdermal PCA Systems
- By Drug Type: Opioid Analgesics, Non-Opioid Analgesics, Local Anesthetics, Combination Analgesics
- By End User: Hospitals, Ambulatory Surgical Centers, Home Care Settings, Pain Clinics
- By Application: Postoperative Pain Management, Cancer Pain Management, Chronic Pain Management, Labor and Delivery Pain Management
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Intravenous PCA Pumps leads By Product Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 13 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 268 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.162 →
- 11 Company Profiles 13 players: SWOT & benchmarking p.170 →
Full report · locked preview
Everything inside the Patient-controlled Analgesic Pump Market report
A complete, evidence-based study - 11 chapters and 112 sections covering market size, segmentation across 4 axes, regional analysis and 13 company profiles, forecast to 2033.
Segmentation covered
Product Type 4
Drug Type 4
End User 4
Application 4
Companies profiled
Baxter International Inc.
B. Braun Melsungen AG
Smiths Medical (a division of ICU Medical
Inc.)
Hospira (a Pfizer company)
Fresenius Kabi AG
Moog Inc.
Nipro Corporation
Terumo Corporation
Stryker Corporation
CareFusion Corporation (a BD company)
Natus Medical Incorporated
+1 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
13 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Baxter International Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →B. Braun Melsungen AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Smiths Medical (a division of ICU Medical
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Inc.)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Hospira (a Pfizer company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Fresenius Kabi AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →Moog Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Nipro Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Terumo Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Stryker Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →CareFusion Corporation (a BD company)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.214 →Natus Medical Incorporated
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.220 →Zyno Medical
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$3,150M by 2033 · 5.1% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Intravenous PCA Pumps57.5
- Epidural PCA Pumps15.1
- Subcutaneous PCA Pumps15.1
- Transdermal PCA Systems12.2
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$699.2M → $1,158M · 6.5%
Europe$487.3M → $750.5M · 5.5%
Asia Pacific$445.0M → $623.0M · 4.3%
Latin America$275.5M → $387.6M · 4.4%
Middle East and Africa$211.9M → $298.4M · 4.4%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →5.032026
5.042027
5.062028
5.062029
5.082030
5.102031
5.112032
5.132033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Baxter International Inc.18.8
- B. Braun Melsungen AG21.9
- Smiths Medical (a division of ICU Medical7.1
- Inc.)6.4
- Hospira (a Pfizer company)9.6
- Fresenius Kabi AG8.2
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Product Type28.2%
Drug Type19.9%
End User21.3%
Application30.7%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America36.0
- Europe23.3
- Asia Pacific19.4
- Latin America12.0
- Middle East and Africa9.3
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Baxter International Inc. | 79 | 77 | 76 | 85 | 95 | 91 | 84 |
| B. Braun Melsungen AG | 81 | 71 | 89 | 81 | 82 | 93 | 83 |
| Smiths Medical (a division of ICU Medical | 64 | 72 | 69 | 66 | 63 | 83 | 70 |
| Inc.) | 59 | 77 | 81 | 71 | 73 | 68 | 72 |
| Hospira (a Pfizer company) | 74 | 70 | 61 | 73 | 69 | 57 | 67 |
| Fresenius Kabi AG | 47 | 51 | 69 | 56 | 70 | 68 | 60 |
| Moog Inc. | 57 | 47 | 61 | 48 | 45 | 52 | 52 |
| Nipro Corporation | 46 | 57 | 50 | 50 | 58 | 45 | 51 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Baxter International Inc.
- B. Braun Melsungen AG
- Smiths Medical (a division of ICU Medical
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Baxter International Inc. | ✓ | ◐ | ◐ | ◐ | ✓ | ✓ |
| B. Braun Melsungen AG | ✓ | ◐ | ✓ | ◐ | ◐ | ✓ |
| Smiths Medical (a division of ICU Medical | − | ◐ | ◐ | − | ◐ | ◐ |
| Inc.) | − | ◐ | ✓ | ✓ | ◐ | ✓ |
| Hospira (a Pfizer company) | ✓ | ◐ | ✓ | ✓ | ◐ | − |
| Fresenius Kabi AG | ◐ | − | ✓ | − | ◐ | ✓ |
| Moog Inc. | ◐ | − | ✓ | ◐ | − | ◐ |
| Nipro Corporation | − | ◐ | ◐ | − | ◐ | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Baxter International Inc.84
2B. Braun Melsungen AG83
3Inc.)72
4Smiths Medical (a division of ICU Medical70
5Hospira (a Pfizer company)67
6Fresenius Kabi AG60
7Moog Inc.52
8Nipro Corporation51
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Baxter International Inc.B. Braun Melsungen AG
Challenger3
Strong scale, closing on the leaders.
Smiths Medical (a division of ICU MedicalInc.)Hospira (a Pfizer company)
Contender1
Focused players with pockets of strength.
Fresenius Kabi AG
Niche2
Specialists in a single segment or region.
Moog Inc.Nipro Corporation
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Product Type in North America, then scale across Patient-controlled Analgesic Pump Market — a $33M beachhead inside a $611M market.
Beachhead (SOM)$33Mobtainable near-term
Serviceable (SAM)$230Mreachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion86 fit
Intravenous PCA Pumps
Best fit — highest urgency & budget in Product Type.
Economic buyer79 fit
Epidural PCA Pumps
Strong fit — clear ROI and a fast path to value.
End user68 fit
Subcutaneous PCA Pumps
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Product Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Drug Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales46%
Partner / channel26%
Digital / self-serve20%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Product Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Patient-controlled Analgesic Pump Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified38%
Sales qualified26%
Evaluation11%
Closed-won6%
$17.2KCAC
$103KLTV
6.0:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Patient-controlled Analgesic Pump Market is a resilient opportunity — $656M by 2033, compounding at 4.5%.
TAM · 2025$460Mtoday
TAM · 2033$656Mforecast
CAGR4.5%2027–2033
Cumulative$4.98Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$656MTotal addressable market
SAM$251MServiceable available market
SOM$44MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →4.5% CAGR
Demand compounds through 2033, outpacing GDP across Product Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Product Type moving from early to mainstream — durable secular demand.
Consolidation upside
13+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$656MLarge & growingTAM by 2033 at 4.5% CAGR
$251MServiceable nowreachable with today’s model
$44MBeachhead winobtainable near-term share
13+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$512MBear2.9% CAGR
$656MBase4.5% CAGR
$840MBull6.0% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Drug Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Patient-controlled Analgesic Pump Market — a $1.34B market by 2033. Plan: grow share from 7.7% to 15.1%.
Market size · 2033$1.34Btotal addressable
Market CAGR3.9%2027–2033
Target share15.1%from 7.7% today
Revenue ambition$202Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.7% | 15.1% | At risk |
| Revenue | $106M | $202M | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 29.3% | 38.9% | On track |
| Customer retention | 87.0% | 95.3% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Product Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Drug Type capability
A defensible second engine — invest in Drug Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Product Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Drug Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $25M capacity & capability investment
- Greenlight bolt-on M&A in Drug Type
- Authorise North America expansion plan
- Fund R&D program for Product Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossAhead
- Input-cost & supply riskAhead
- Regulatory / policy changeAt risk
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Patient-controlled Analgesic Pump Market conversation — a $9.41B market you can size, segment and defend in minutes.
Market size · 2033$9.41Btotal opportunity
Growth7.5%CAGR to 2033
Addressable buyers1,576+accounts in scope
Typical ROI5.9×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Product Type
Goal Grow share in Product Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.9×return on cost, year one
< 3 mopayback period
$98K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
13+players profiled in this market
Coverage includes
Baxter International Inc.B. Braun Melsungen AGSmiths Medical (a division of ICU MedicalInc.)Hospira (a Pfizer company)Fresenius Kabi AGMoog Inc.Nipro Corporation+5 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Patient-controlled Analgesic Pump Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Patient-controlled Analgesic Pump Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Patient Controlled Analgesia Pump (PCA Pump) Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportPatient-Controlled Analgesia (PCA) Pump Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportPatient Clothes Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportPatient Cleansing Products Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportPatient Circuit Market
Market size, share, segmentation and regional forecast.
$4.0B market · 2025 base year
View reportPatient Chair Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportPatient Centered Medical Home Service Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportPatient Care Monitoring Systems Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportPatient Care Monitoring Equipment Market
Market size, share, segmentation and regional forecast.
$1.0B market · 2025 base year
View reportPatient Care Manikins Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportPatient Care Management Software Market
Market size, share, segmentation and regional forecast.
$883M market · 2025 base year
View reportPatient Blood Pressure Monitor Market
Market size, share, segmentation and regional forecast.
$511M market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.